In terms of BRD9 expression in normal prostate, primary, and metastatic PCa, in the Grasso cohort, there was no significant difference (p = 0.9268) in BRD9 expression between normal prostate and primary PCa; however, there was a significant increase in BRD9 expression in the metastatic PCa group, both when compared to benign prostate (p = 0.0025) and primary PCa (p = 0.0016) groups (Figure 1H). This evidence concerns the gene BRD9 and posterior cortical atrophy.